Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker for its ADCT-402 (loncastuximab tesirine)

 Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker for its ADCT-402 (loncastuximab tesirine)

Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker for its ADCT-402 (loncastuximab tesirine)

Shots:

  • ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • The focus of the collaboration is to develop innovative cancer therapies, highlighting the potential of Freenome’s platform providing tumor and immune signatures for hematological cancers in addition to solid tumors
  • Freenome’s multiomics platform detects biological signals from a routine blood draw, integrating assays for cell-free DNA, methylation, and proteins and incorporates a multidimensional view of both tumor- and immune-derived signatures enabling the early detection of cancer

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: ADC Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post